ArticleAlzheimer's research & therapy2021
Prodromal frontotemporal dementia: clinical features and predictors of progression.
Article in Alzheimer's research & therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Early detection of diseases causing dementia using digital navigation and gait measures: A systematic review of evidence.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Pooled it
- Temporal order of clinical, imaging, and biomarker changes in frontotemporal lobar degeneration-associated syndromes.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- "It seems enormously valuable to me." Perspectives of Dutch (potential) carriers of genetic FTD on onset-predictive biomarker testing.Alzheimer's research & therapy · 2025Article
- AI-Y: An AI Checklist for Population Ethics Across the Global Context.Current epidemiology reports · 2025Review
- Individualized, cross-validated prediction of future dementia using cognitive assessments in people with mild cognitive symptoms.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Blood-Based Biomarkers in Frontotemporal Dementia: A Narrative Review.International journal of molecular sciences · 2024Review
- Cognitive dispersion and its functional relevance in behavioral variant frontotemporal dementia and prodromal behavioral variant frontotemporal dementia.Neuropsychology · 2024Article
- Diagnostic accuracy of research criteria for prodromal frontotemporal dementia.Alzheimer's research & therapy · 2024Article
- The pursuit for markers of disease progression in behavioral variant frontotemporal dementia: a scoping review to optimize outcome measures for clinical trials.Frontiers in aging neuroscience · 2024Article
- Frontotemporal Dementia, Where Do We Stand? A Narrative Review.International journal of molecular sciences · 2023Review
- Classification accuracy of blood-based and neurophysiological markers in the differential diagnosis of Alzheimer's disease and frontotemporal lobar degeneration.Alzheimer's research & therapy · 2022Article
- Behavioral Reserve in Behavioral Variant Frontotemporal Dementia.Frontiers in aging neuroscience · 2022Article
- Differences and similarities between familial and sporadic frontotemporal dementia: An Italian single-center cohort study.Alzheimer's & dementia (New York, N. Y.) · 2022Article
- Impairments in knowledge of social norms in presymptomatic, prodromal, and symptomatic frontotemporal dementia.Alzheimer's & dementia (Amsterdam, Netherlands)Article
- Modeling contributions of cognition and apathy to functional impairment in younger-onset dementia.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 3 countries.
Funding
Abstract
backgroundThe prodromal phase of frontotemporal dementia (FTD) is still not well characterized, and conversion rates to dementia and predictors of progression at 1-year follow-up are currently unknown.
methodsIn this retrospective study, disease severity was assessed using the global CDR plus NACC FTLD. Prodromal FTD was defined to reflect mild cognitive or behavioural impairment with relatively preserved functional independence (global CDR plus NACC = 0.5) as well as mild, moderate and severe dementia (classified as global CDR plus NACC = 1, 2, 3, respectively). Disease progression at 1-year follow-up and serum NfL measurements were acquired in a subgroup of patients.
resultsOf 563 participants, 138 were classified as prodromal FTD, 130 as mild, 175 as moderate and 120 as severe FTD. In the prodromal and mild phases, we observed an early increase in serum NfL levels followed by behavioural disturbances and deficits in executive functions. Negative symptoms, such as apathy, inflexibility and loss of insight, predominated in the prodromal phase. Serum NfL levels were significantly increased in the prodromal phase compared with healthy controls (average difference 14.5, 95% CI 2.9 to 26.1 pg/mL), but lower than in patients with mild FTD (average difference -15.5, 95% CI -28.4 to -2.7 pg/mL). At 1-year follow-up, 51.2% of patients in the prodromal phase had converted to dementia. Serum NfL measurements at baseline were the strongest predictors of disease progression at 1-year follow-up (OR 1.07, 95% CI 1.03 to 1.11, p < 0.001).
conclusionsProdromal FTD is a mutable stage with high rate of progression to fully symptomatic disease at 1-year follow-up. High serum NfL levels may support prodromal FTD diagnosis and represent a helpful marker to assess disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.